Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) Completed Phase 2 Trials for Flu caused by Influenza Prevention

IndicationsStatusPurposePhase
CompletedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
https://clinicaltrials.gov/ct2/show/Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
https://clinicaltrials.gov/ct2/show/2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
https://clinicaltrials.gov/ct2/show/Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children
https://clinicaltrials.gov/ct2/show/Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly
https://clinicaltrials.gov/ct2/show/Influenza Vaccine in Pregnant Women
https://clinicaltrials.gov/ct2/show/Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A
https://clinicaltrials.gov/ct2/show/Study to Evaluate an Influenza Vaccine Candidate
https://clinicaltrials.gov/ct2/show/Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
https://clinicaltrials.gov/ct2/show/Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over
https://clinicaltrials.gov/ct2/show/Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children
https://clinicaltrials.gov/ct2/show/Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
https://clinicaltrials.gov/ct2/show/Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
https://clinicaltrials.gov/ct2/show/Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults
https://clinicaltrials.gov/ct2/show/Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate
https://clinicaltrials.gov/ct2/show/Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age
https://clinicaltrials.gov/ct2/show/Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate
https://clinicaltrials.gov/ct2/show/Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate
https://clinicaltrials.gov/ct2/show/Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population
https://clinicaltrials.gov/ct2/show/Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate
https://clinicaltrials.gov/ct2/show/Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population